REGULATED INFORMATION
GHENT, Belgium, 22 August 2012 - Ablynx [Euronext Brussels: ABLX] today
announced its results for the six-month period ending 30 June 2012, which have
been prepared in accordance with the IAS 34 "Interim Financial Reporting" as
adopted by the European Union. The highlights of the developments in its product
pipeline and partnerships are also provided.
Click here to access the live audio webcast presentation tomorrow 23 August
2012 at 16h CET/10am EST;
call number +32 (0)2 400 34 63.
Operating highlights
* Seven Nanobody-based products in clinical development across multiple
disease areas
* Further success achieved under the Strategic Alliance with Boehringer
Ingelheim with three new development candidates selected and FTE payments
within the alliance extended for two years (€6.6M of which €5M received)
* Clinical Trials Application filed by Boehringer Ingelheim for its
Alzheimer's Nanobody
* IND filed by Novartis for the Nanobody, TAS266, directed against Death
Receptor 5 (DR5)
* Published compelling 48-week Phase II data for the anti-TNFa Nanobody
ozoralizumab (ATN-103) in patients with RA
Financial highlights
* Revenues were €16.6 million, up 30% compared to 2011
* Net cash burn was €7.3 million, down by 69% compared to 2011
* Strong financial position with €76.5 million in cash, cash equivalents,
restricted cash and short-term investments
Commenting on the half-year 2012 results, Dr Edwin Moses, Chairman and CEO of
Ablynx, said:
"We are very pleased with the progress we have made during the first six months
of the year, both operationally and financially. As promised, we carefully
managed our net cash burn while still investing substantially in our proprietary
and partnered programmes. We look forward to the remainder of the year during
which we expect potential proof-of-concept data with the anti-IL-6R Nanobody,
ALX-0061, in RA, Phase I data for the first inhaled Nanobody, ALX-0171,
additional milestones from our partners and potential new deals."
About Ablynx
Ablynx is a biopharmaceutical company engaged in the discovery and development
of Nanobodies(®), a novel class of therapeutic proteins based on single-domain
antibody fragments, for a range of serious human diseases, including
inflammation, haematology, oncology and pulmonary disease. Today, the Company
has approximately 25 programmes in its pipeline and seven Nanobodies are at the
clinical development stage. Ablynx has ongoing research collaborations and
significant partnerships with major pharmaceutical companies, including
Boehringer Ingelheim, Merck Serono, and Novartis. The Company is headquartered
in Ghent, Belgium. More information can be found on www.ablynx.com.
For more information, please contact
Ablynx:
Dr Edwin Moses
Chairman and CEO
t:Â Â +32 (0)9 262 00 07
m: +44 (0)7771 954 193 /
    +32 (0)473 39 50 68
e:Â edwin.moses@ablynx.com
Marieke Vermeersch
Investor Relations Manager
t:Â Â +32 (0)9 262 00 82
m: +32 (0)479 49 06 03
e:Â marieke.vermeersch@ablynx.com
Follow us on Twitter @AblynxABLX
M:Communications:
Mary-Jane Elliott, Amber Bielecka, Claire Dickinson
t:Â Â +44 207 920 2330
e:Â ablynx@mcomgroup.com
Complete version of the press release:
http://hugin.info/137912/R/1635607/525415.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Ablynx via Thomson Reuters ONE
[HUG#1635607]
